Dermata Therapeutics Inc (DRMA)

[tw0122]

Flying to $1.10 back to .70s back to .80s has volume

[$oldier Hard]

Gap filled from this mornings opening and may be consolidating now.

[mick]

https://www.otcmarkets.com/stock/DRMA

[glenn1919]

DRMA................................https://stockcharts.com/h-sc/ui?s=DRMA&p=W&b=5&g=0&id=p86431144783

[$oldier Hard]

$DRMA low floater 2.9 mil, heavily oversold, might have to start buying a few of this one.

[Monksdream]

DRMA new 52 week low

[Monksdream]

DRMA new 52 wewek low

[Monksdream]

DRMA under $2

[mick]

https://www.otcmarkets.com/stock/DRMA

[mick]

$drma Recent DRMA News
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:18:20 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:16:30 PM

[mick]

$drma
Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:31:21 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/28/2023 04:15:22 AM

[mick]

$DRMA Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 07/27/2023 08:50:42 PM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/07/2023 08:21:18 PM

[mick]

nice chart
https://stockcharts.com/c-sc/sc?s=DRMA&p=D&yr=1&mn=1&dy=0&i=p24986097784&a=1113701411&r=1693595168175

[The Night Stalker]

good news and it goes red

[The Night Stalker]

good news and it goes red

[The Night Stalker]

https://www.otcmarkets.com/stock/DRMA/news/story?e&id=2564690

[tw0122]

Run run $1.90s

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=1&mn=1&dy=0&id=p24986097784&listNum=23&a=1113701411

[The Night Stalker]

hit 1.94 0n a few blocks, good news and a big volume spike runs it

[The Night Stalker]

·

To elect three director nominees to serve as directors until the 2026 annual meeting of stockholders;

·

To ratify the appointment of Mayer Hoffman McCann P.C. as our independent registered public accounting firm for the year ending December 31, 2023;

·

To approve an amendment to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) to increase the number of the shares of common stock authorized for issuance thereunder by 513,150 shares to 629,069 shares; and

·

To consider any other matters that may properly come before the Annual Meeting.



Only stockholders of record at the close of business on June 5, 2023 are entitled to receive notice of and to vote at the Annual Meeting or any postponement or adjournment thereof.

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=drma&p=W&yr=0&mn=11&dy=25&id=p34307943936&a=1105106922&listNum=2

[The Night Stalker]

next push breaks 2.09

[The Night Stalker]

next push breaks 2.09

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=1&mn=1&dy=0&id=p24986097784&listNum=23&a=1113701411

[The Night Stalker]

https://stockcharts.com/h-sc/ui?s=drma&p=D&yr=1&mn=1&dy=0&id=p24986097784&listNum=23&a=1113701411

[The Night Stalker]

drop the news

[The Night Stalker]

need a pump

[The Night Stalker]

the science here beats current acne twice daily applications, once weekly application is unheard of

doubled up at 1.57. so im averaged down for this

from a faggot chart perspective it may be ready if news is good

https://finance.yahoo.com/chart/DRMA?technical=all&ncid=dcm_306158732_490172245_127172993#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

[The Night Stalker]

its a process it doesn't happen over night - Jeffery Dahmer

[The Night Stalker]

next 2 weeks if all goes well with FDA we will get our push

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."

[The Night Stalker]

can break 2.09 this week

[The Night Stalker]

can break 2.09 this week

[The Night Stalker]

starting

[The Night Stalker]

starting

[The Night Stalker]

https://stockcharts.com/freecharts/gallery.html?drma

[The Night Stalker]

We look forward to receiving feedback from FDA on our End of Phase 2 meeting package by the end of June 2023. Assuming positive feedback, we plan to quickly initiate our DMT310 Phase 3 program in moderate-to-severe acne."

[The Night Stalker]

https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100

[The Night Stalker]

https://www.barchart.com/stocks/quotes/DRMA/technical-chart?plot=BAR&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=DRMA&grid=1&height=500&studyheight=100

[The Night Stalker]

still here, market has twice daily creams for acne, but this is the first once weekly application, hit 2.08 other day, the number ratio has a solid effectiveness rate here. doubled up at 1.57. with FDA event in coming weeks

[The Night Stalker]

nasTy

[The Night Stalker]

nasTy

[The Night Stalker]

once weekly acne application current market has twice daily cream 10 billion market at 5.2m marketcap

[The Night Stalker]

we see higher volume days ahead-

[The Night Stalker]

- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -

- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -

- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -

SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("De

[The Night Stalker]

- DMT310 once-weekly topical treatment demonstrated statistically significant improvements at all time points in the three primary endpoints, inflammatory lesion count, noninflammatory lesion count, and Investigator Global Assessment (IGA) -

- DMT310 significantly reduced inflammatory lesions by 45% after only 4 treatments in patients with moderate-to-severe acne -

- FDA responses to DMT310 End of Phase 2 meeting package expected by the end this month -

SAN DIEGO, CA / ACCESSWIRE / June 8, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("De

[The Night Stalker]

want to see higher volume days and the milestone will see big push

[The Night Stalker]

going higher